1Dellenbach P, Thomas JL, Guerin V, et al. Topical treatment of vaginal candidosis with sertaconasole and econazole sustained-release suppositories. Int J Gynaecol Obstet, 2000, 71 :S47 - S52.
2Oku Y, Sakuma K, Yokoyama K, et al. Fungicidal activity of liranaftate against Trichophyton rubrum. Nippon Ishinkin Gakkai Zasshi,2002, 43:181 -187.
3Niwano Y, Tabuchi T, Kanai K, et al. Short-term topical therapy of experimental tinea pedis in guinea pigs with lanoconazole, a new imidazole antimycotic agent. Antimicrob Agents Chemother, 1995, 39:2353 - 2355.
4Soga F, Katoh N, Kishimoto S. Contact dermatitis due to lanoconazole, cetyl alcohol and diethyl sebacate in lanoconazole cream. Contact Dermatitis, 2004, 50:49 - 50.
5Gebhart R J, Espinel-Ingroff A, Shadomy S. In vitro susceptibility studies with oxiconazole ( Ro 13 - 8996 ). Chemotherapy, 1984,30:244 - 247.
6Jegasothy BV, Pakes GE. Oxiconazole nitrate: pharmacology, efficacy, and safety of a new imidasole antifungal agent. Clin Ther, 1991,13:126 - 141.
8Gugnani HC, Gugnani A, Malachy O. Sulconazole in the therapy of dermatomycoses in Nigeria. Mycoses, 1997, 40:139 - t41.
9Bigardi AS, Pigatto PD, Altomare G. Allergic contact dermatitis due to sulconazole. Contact Dermatitis, 1992, 26:281 - 282.
10Takahashi H. Phase Ⅲ controlled trial of M- 732(liranaftate) cream in patients with tinea cruris evaluating with In vitro incubation results.Nishinippon Hifuka( Nishinihon J Dermatol), 2000,62:788 - 802.
